Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Cell Cycle – Theory and Application to Cancer

The Cell Cycle – Theory and Application to Cancer The division cycle of normal mammalian cells is governed by a highly coordinated network of interacting mechanisms that ensure a correct succession of the biochemical and biophysical events culminating in mitosis. A family of specific protein kinases, the Cdks, constitute the motor element of cell cycle progression. Their function is regulated at several levels: 1. association with a cyclin subunit situates their activity in different phases of the cell cycle; 2. sequential phosphorylation and dephosphorylation on specific amino acid residues is required for their final activation; 3. their activity can be modulated by complexing with members of the cyclin-dependent kinase inhibitor family (Cdkls). The latter function to a large extent as effectors of signals emitted by cell surface receptors or internal sensors of defective biochemical and biophysical states termed checkpoints. While the fate of cells is largely influenced by external factors throughout Gl phase, an intrinsic program becomes responsible for cell cycle progression after the passage of the ‘restriction point’ at the Gl/S boundary. This crucial transition is controlled by a checkpoint mechanism in which the concerted action of p53 and the retinoblastoma protein may induce either a cell cycle arrest or apoptosis in response to genomic damage. Several other checkpoint functions regulate the entry into mitosis by assessing the completion of DNA replication and correct chromosome attachment to the spindle apparatus. Finally, the number of possible cell divisions is predetermined by the number of small oligonucleotide repeats at the utmost chromosome ends, the telomeres. Checkpoint mechanisms can be disrupted by viral oncoproteins or gene mutations. Loss of their function is likely to result in genomic destabili-zation and gene amplification, which again may allow for chromosome aberrations and, as several connections link the genome to the cell cycle machinery, may permit unrestrained cell growth. The majority of the cell cycle-related proteins, however, do not qualify for monitoring the prolifer-ative activity or the tumor growth fraction. To date, only three proteins: p345 (Ki-67), pl70 (topoisomerase II-alpha), and p100 (S-phase protein) have been identified as selective indicators of cellular proliferation. The first two recognize all cell cycle phases except GO, whereas the latter is specifically expressed in S, G2, and M phase cells. Application of antibodies to these proteins in clinical pathology was found to be highly relevant for the prediction of tumor biology and clinical courses. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology Research and Treatment Karger

The Cell Cycle – Theory and Application to Cancer

Oncology Research and Treatment , Volume 19 (6): 9 – Jan 1, 1996

Loading next page...
 
/lp/karger/the-cell-cycle-theory-and-application-to-cancer-fcJr7ubvPU

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1996 S. Karger AG, Basel
ISSN
2296-5270
eISSN
2296-5262
DOI
10.1159/000218858
Publisher site
See Article on Publisher Site

Abstract

The division cycle of normal mammalian cells is governed by a highly coordinated network of interacting mechanisms that ensure a correct succession of the biochemical and biophysical events culminating in mitosis. A family of specific protein kinases, the Cdks, constitute the motor element of cell cycle progression. Their function is regulated at several levels: 1. association with a cyclin subunit situates their activity in different phases of the cell cycle; 2. sequential phosphorylation and dephosphorylation on specific amino acid residues is required for their final activation; 3. their activity can be modulated by complexing with members of the cyclin-dependent kinase inhibitor family (Cdkls). The latter function to a large extent as effectors of signals emitted by cell surface receptors or internal sensors of defective biochemical and biophysical states termed checkpoints. While the fate of cells is largely influenced by external factors throughout Gl phase, an intrinsic program becomes responsible for cell cycle progression after the passage of the ‘restriction point’ at the Gl/S boundary. This crucial transition is controlled by a checkpoint mechanism in which the concerted action of p53 and the retinoblastoma protein may induce either a cell cycle arrest or apoptosis in response to genomic damage. Several other checkpoint functions regulate the entry into mitosis by assessing the completion of DNA replication and correct chromosome attachment to the spindle apparatus. Finally, the number of possible cell divisions is predetermined by the number of small oligonucleotide repeats at the utmost chromosome ends, the telomeres. Checkpoint mechanisms can be disrupted by viral oncoproteins or gene mutations. Loss of their function is likely to result in genomic destabili-zation and gene amplification, which again may allow for chromosome aberrations and, as several connections link the genome to the cell cycle machinery, may permit unrestrained cell growth. The majority of the cell cycle-related proteins, however, do not qualify for monitoring the prolifer-ative activity or the tumor growth fraction. To date, only three proteins: p345 (Ki-67), pl70 (topoisomerase II-alpha), and p100 (S-phase protein) have been identified as selective indicators of cellular proliferation. The first two recognize all cell cycle phases except GO, whereas the latter is specifically expressed in S, G2, and M phase cells. Application of antibodies to these proteins in clinical pathology was found to be highly relevant for the prediction of tumor biology and clinical courses.

Journal

Oncology Research and TreatmentKarger

Published: Jan 1, 1996

Keywords: Checkpoint; p53; Rb; Cell cycle; Cyclin; Cyclin-dependent kinase; Cyclin-kinase inhibitors

There are no references for this article.